Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + ARX788 neoadjuvant phase II study in HER2-positive breast cancer with poor response to trastuzumab/pertuzumab
ChiCTR2100048560Phase 2Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib and anvatabart opadotin in breast cancer, sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Residual tumor burden classification. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
pyrotinibanvatabart opadotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100048560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048560.